Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down – Time to Sell?

Shares of Merck KGaA (OTCMKTS:MKGAF – Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $167.12, but opened at $160.60. Merck KGaA shares last traded at $169.40, with a volume of 4 shares trading hands.

Merck KGaA Price Performance

The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The stock has a market cap of $21.40 billion, a P/E ratio of 25.27 and a beta of 0.96. The firm’s fifty day moving average price is $161.64 and its 200-day moving average price is $152.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Elefante Mark B bought a new stake in Merck KGaA during the second quarter worth about $617,000. Ames National Corp bought a new position in shares of Merck KGaA during the second quarter valued at $1,009,000. Notis McConarty Edward bought a new position in shares of Merck KGaA during the second quarter valued at $1,304,000. North Star Asset Management Inc. purchased a new position in shares of Merck KGaA in the 2nd quarter worth about $1,411,000. Finally, Pinnacle Holdings LLC purchased a new position in shares of Merck KGaA in the 2nd quarter worth about $1,487,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.

About Merck KGaA

(Get Free Report)

Merck KGaA is a science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is distinct from the U.S.-based Merck & Co. and operates internationally across healthcare, life science and electronics. Its Healthcare business develops prescription medicines, including treatments in areas such as oncology, neurology, immunology and fertility. The Life Science business supplies products and services used in research, biotechnology and pharmaceutical manufacturing, including laboratory materials, equipment and solutions for bioprocessing.

See Also

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.